E
Estrella Immunopharma Inc
NASDAQ:ESLA
Estrella Immunopharma Inc
NASDAQ:ESLA
Price:
1.05
USD
0.96%
Market Closed
Market Cap:
$44.1m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
E
|
Estrella Immunopharma Inc
NASDAQ:ESLA
|
US |
|
Riken Corundum Co Ltd
TSE:5395
|
JP |
Income Statement
Earnings Waterfall
Estrella Immunopharma Inc
Estrella Immunopharma Inc
Income Statement
Estrella Immunopharma Inc
Estrella Immunopharma Inc
Currency: USD
| Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | ||||||||||||||||
| Operating Expenses |
(2)
|
(1)
|
(2)
|
(2)
|
(11)
|
(3)
|
(3)
|
(4)
|
(7)
|
(9)
|
(4)
|
(10)
|
(12)
|
(13)
|
(13)
|
|
| Selling, General & Administrative |
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(2)
|
(2)
|
(3)
|
(3)
|
(2)
|
(2)
|
(3)
|
(3)
|
(3)
|
(3)
|
|
| Research & Development |
(1)
|
0
|
0
|
0
|
(10)
|
(0)
|
(1)
|
(1)
|
(4)
|
(6)
|
(3)
|
(8)
|
(9)
|
(10)
|
(10)
|
|
| Other Operating Expenses |
0
|
(1)
|
(1)
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
(2)
N/A
|
(1)
+26%
|
(2)
-26%
|
(2)
N/A
|
(11)
-608%
|
(3)
+76%
|
(3)
-22%
|
(4)
-10%
|
(7)
-107%
|
(9)
-21%
|
(4)
+50%
|
(10)
-137%
|
(12)
-15%
|
(13)
-12%
|
(13)
+3%
|
|
| Pre-Tax Income | ||||||||||||||||
| Interest Income Expense |
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(2)
N/A
|
(1)
+42%
|
(1)
+6%
|
(1)
+12%
|
(11)
-1 272%
|
(2)
+82%
|
(3)
-47%
|
(3)
-14%
|
(7)
-114%
|
(9)
-21%
|
(4)
+50%
|
(10)
-137%
|
(12)
-15%
|
(13)
-12%
|
(13)
+3%
|
|
| Net Income | ||||||||||||||||
| Tax Provision |
0
|
0
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Income from Continuing Operations |
(2)
|
(1)
|
(1)
|
(1)
|
(11)
|
(2)
|
(3)
|
(3)
|
(7)
|
(9)
|
(4)
|
(10)
|
(12)
|
(14)
|
(13)
|
|
| Net Income (Common) |
(2)
N/A
|
(1)
+42%
|
(1)
-2%
|
(1)
+9%
|
(11)
-1 121%
|
(2)
+81%
|
(3)
-40%
|
(3)
-14%
|
(7)
-113%
|
(9)
-21%
|
(4)
+50%
|
(10)
-137%
|
(12)
-15%
|
(14)
-12%
|
(13)
+3%
|
|
| EPS (Diluted) |
-0.05
N/A
|
-0.16
-220%
|
-0.43
-169%
|
-0.39
+9%
|
-0.32
+18%
|
-2.05
-541%
|
-0.08
+96%
|
-0.09
-12%
|
-0.2
-122%
|
-0.24
-20%
|
-0.12
+50%
|
-0.28
-133%
|
-0.33
-18%
|
-0.37
-12%
|
-0.35
+5%
|
|
Switch to:
Switch to:
See Also
Discover More
